Comparison of Steady-State Pharmacokinetics of Donepezil Transdermal Delivery System with Oral Donepezil
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Background: Donepezil is approved for treatment of dementia of the Alzheimer type and is currently available only in tablet forms in the United States. Objective: To compare steady-state pharmacokinetics of once-weekly 10-mg/d and 5-mg/d Corplex™ donepezil transdermal delivery systems (TDS) with once-daily 10-mg oral donepezil. Methods: Open-label, randomized, crossover study (NCT04617782) enrolled healthy participants aged 18–55 years. All participants received 5-mg/d donepezil TDS during the 5-week Period 1, followed by 10-mg/d TDS or 10-mg/d oral donepezil in the 5-week Period 2; treatments were switched in Period 3. Bioequivalence was assessed at steady state on Week 5. Results: All 60 enrolled participants received 5-mg/d TDS, 55 received 10-mg/d TDS, and 56 received oral donepezil. Adjusted geometric mean ratio (% [90% CI]) for maximum plasma concentration and area under the plasma concentration versus time curve (0–168 h) were 88.7 (81.7–96.2) and 108.6 (100.5–117.4) for 10-mg/d and 86.1 (79.8–92.9) and 105.3 (97.6–113.6) for dose-normalized 5-mg/d TDS and were generally within the 80% –125% range for establishing bioequivalence with oral donepezil. Skin adhesion was similar for both TDSs (>80% of patches remaining ≥75% adhered throughout the wear period). Overall incidence of adverse events (AEs) was similar across treatments. Compared with 10-mg/d TDS, oral donepezil was associated with higher incidence of gastrointestinal and nervous system AEs (14.5% versus 53.6% and 14.5% versus 30.4%, respectively). Conclusion: Donepezil TDSs are bioequivalent to oral donepezil at steady state and have a safety profile that supports their use in treating dementia of the Alzheimer type.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Its weekly dosing frequency showed bioequivalence to daily oral administration at the same dosage while presenting fewer gastrointestinal adverse events than oral administration.”
From Recent advances in Alzheimer's disease: Mechanisms, clinical trials and new drug development strategies. (2024) · cites this paper as [405]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157 · cited 2×
“The safety evaluation was based on AEs, laboratory evaluations, physical examinations, electrocardiogram (ECG) parameters, Columbia Suicide Severity Rating Scale (C-SSRS), and skin irritation scores.”
MethodRogers, S. L. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.9.1021 · Cited by 773
Hansen, R. A., Webb, A. P., Moore, C. G., Gartlehner, G., Jonas, D. E., & Morgan, L. C. (2008) · PubMed Central · doi:10.17615/ae8c-2p76 · Cited by 691
Challenges and Opportunities in dermal/transdermal Delivery
Paudel, K. S., Milewski, M., Swadley, C. L., Brogden, N. K., Ghosh, P., & Stinchcomb, A. L. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.16 · Cited by 616
Doody, R. S. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.427 · Cited by 362
Winblad, B., Cummings, J., Andreasen, N., Grossberg, G., Onofrj, M., Sadowsky, C., Zechner, S., Nagel, J., & Lane, R. (2007) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1788 · Cited by 286
Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease
Watts, R. L., Jankovic, J., Waters, C., Rajput, A., Boroojerdi, B., & Rao, J. (2007) · Neurology · doi:10.1212/01.wnl.0000252355.79284.22 · Cited by 249
Farlow, M. R., Salloway, S., Tariot, P. N., Yardley, J., Moline, M. L., Wang, Q., Brand-Schieber, E., Zou, H., Hsu, T., & Satlin, A. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.06.019 · Cited by 186
Self-citationOne-sided confidence intervals in discrete distributions
Cai, T. (2004) · Journal of Statistical Planning and Inference · doi:10.1016/j.jspi.2004.01.005 · Cited by 163
Transdermal donepezil on the treatment of Alzheimer's disease
Stefano, A. D., Sozio, Cerasa, & Marinelli, L. (2012) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s16089 · Cited by 71
Cited by
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Transdermal Drug Delivery Systems: Methods for Enhancing Skin Permeability and Their Evaluation
Бахрушина, Е. О., Shumkova, M. M., Avdonina, Y. V., Ananian, A. A., Babazadeh, M., Pouya, G., Grikh, V. V., Zubareva, I. M., Kosenkova, S. I., Krasnyuk, I. I., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17070936 · Cited by 102
“The study concluded that 10 mg transdermal donepezil administered weekly is bioequivalent to 10 mg oral donepezil tablets taken daily [182].”
Intranasal Drug Administration in Alzheimer-Type Dementia: Towards Clinical Applications
Taléns-Visconti, R., de Julián-Ortiz, J. V., Vila-Busó, O., Diez-Sales, O., & Nácher, A. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15051399 · Cited by 59
“Donepezil Oral Tablets Orodispersible tablets [12,13,22] Transdermal Transdermal patches Combination of memantine and donepezil Oral Controlled release capsules [23]”
BackgroundInfluentialAilioaie, L. M., Ailioaie, C., & Litscher, G. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030916 · Cited by 44
Buck, A., Rezaei, K., Quazi, A., Goldmeier, G., Silverglate, B., & Grossberg, G. T. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2355981 · Cited by 14
“…transdermal administration is 91 h and the mean apparent plasma clearance at steady state (CLss/F) is 0.12 L/hr/kg with a steady state volume of distribution of 12–16 L/kg. Oral donepezil has an elimination half-life of 70 h, and the mean apparent plasma clearance (Cl/F) is 0.13–0.19 L/hr/kg [32].”
BackgroundInfluentialLee, J. H., Song, G. J., Hwang, H. S., & Lee, C. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125653 · Cited by 13
Donepezil for cancer-related cognitive impairment: systematic review and meta-analysis
Fornalik, M., Moska, S., Gimła, M., Yabluchanskiy, A., & Pinto, C. B. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01708-w · Cited by 9
“Donepezil’s long half-life of 70 h and high bioavailability allows once-a-day dosing, making it convenient for patients [24–26].”
Kim, M., Kwon, H., Sohn, S., Lee, W. J., Cho, K., & Kim, G. W. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251391820 · Cited by 13
“66 While patches are effective substitutes, they are not as affordable as oral tablets and lack high does like 23 mg. 67 Nevertheless, transdermal patches, namely donepezil patches, have become highly commercialized and universalized.”
Sabbagh, M. N., Mathew, P., & Blau, A. D. (2023) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000578 · Cited by 7
“…results of a previous study showed that the donepezil TDS is associated with fewer treatment-related gastrointestinal disorders than oral donepezil, 11 which potentially could lead to better compliance among patients, although forthcoming real-world evidence will provide more de fi nitive…”
ResultNguyen‐Thi, P., Vo, T. K., Le, H. T., Nguyen, N. T. T., Nguyen, T. T., & Giau, V. V. (2024) · Pharmaceutical Research · doi:10.1007/s11095-024-03718-x · Cited by 7
Zhang, S., Zhang, Q., Xu, R., Ma, J., & Fang, L. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123410 · Cited by 6
Shaheen, A. M., Mousa, M. H. A., Hindam, M. O., El‐Dessouki, A. M., Fahim, S. A., Hal, D. M., Ahmed, S., El‐Shiekh, R. A., & Khalifa, H. O. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1863841 · Cited by 4
Chávez-López, L. M., Silvestre-Martínez, J. H., Lugo-Ibarra, K. C., & Castro-Ceseña, A. B. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149718 · Cited by 3
In vitro, ex vivo and in vivo studies on anti-hypertensive-loaded transdermal and buccal patches
Majee, S. B., Gupti, S., Mishra, T., & Bera, R. (2025) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v15i3.7044 · Cited by 2
Motoi, Y., & Sanjo, N. (2026) · Brain Sciences · doi:10.3390/brainsci16010098 · Cited by 2
“While this has already been demonstrated in healthy volunteers [22], it has not yet been examined in clinical settings.”
Development of Drug-in-Adhesive Patch Formulation for Transdermal Delivery of Pelubiprofen
Lee, M., Han, C.-S., Min, K. H., Kim, D., Park, C., Weon, K.-Y., & Kang, J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121580 · Cited by 1
“TDDS can also provide stable plasma concentrations, minimizing the peak–trough fluctuations commonly observed with oral dosing [10,11].”
Ahmed, S., Allam, A. T., Eid, O., Zaki, E. S., Shaheen, A. M., Al-Nazer, M. A., Shalaby, M. E., El‐Dessouki, A. M., Kotb, S. S., El‐Shiekh, R. A., et al. (2026) · Scientific African · doi:10.1016/j.sciaf.2026.e03640 · Cited by 1
He, Y., Jiang, Z., & Zhang, Y. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001548
“Results of a previous study showed that 10-mg/day and dose-normalized 5-mg/day donepezil TDS are bioequivalent to 10-mg/day of oral donepezil [4] .”
BackgroundAdvances in the Diagnosis and Management of Alzheimer’s Disease
Joshi, P., Tsai, P., Alix, A., & Gopalakrishna, G. (2026) · Advances in Psychiatry and Behavioral Health · doi:10.1016/j.ypsc.2026.05.004
da Silva, P. P., Marques, V. C., Ramos, L. K. S., Filho, J. D. D. S., de Freitas, R. F., Machado, M. G. C., Cardoso, M. V. C., Marques, F. D. S., Vieira, P. M. D. A., Araujo, L. D. S., et al. (2026) · ACS Omega · doi:10.1021/acsomega.6c04903
Yang, I. G., Heo, J. Y., Myung, J. H., Jeong, M. Y., Park, J. S., Kim, D. E., Noh, S. Y., Jeong, M. G., Kim, M. J., Kim, J. Y., et al. (2026) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2026.153735
Topical Donepezil for Cholinergic Modulation in Chronic Wound Repair
Qu, H., Kao, C., & Hakonarson, H. H. (2026) · Wound Repair and Regeneration · doi:10.1111/wrr.70211
“A once-weekly patch sys-tem (ADLARITY) provided bioequivalence to oral 10 mg with lower peak-trough variation and improved tolerability [41, 50].”
Li, X., Li, M., Song, H., Liu, X., Jia, F., Tang, Y., Wu, P., & Wen, Q. (2026) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2026.108063
“Transdermal drug delivery (TDD) can bypass gastrointestinal degradation and hepatic first-pass metabolism while supporting sustained administration, features that are valuable for chronic and localized therapy [1].”
Poonam, Rana, R., Thakur, M., Sharma, A., Pannu, S., Sharma, S., Naman, S., Rani, S., Devi, D., Kumar, V., et al. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1908830
“Safety, tolerance, and ef fi cacy will all increase as a result (144, 145).”
Metadata
- Authors
- Tariot, P. N., Braeckman, R., & Oh, C.
- Affiliations
- Banner Alzheimer’s Institute (US)
- KemPharm (United States) (US)
- Corium Inc., Grand Rapids, MI, USA
- Corresponding author
- Oh, Charles
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2022-10-25
- Volume
- 90
- Issue
- 1
- Pages
- 161-172
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- PMC
- PMC9661317
- OpenAlex
- W4296326377
- Cited by
- 24
- References
- 17
- Citations by year
- 2026: 9 · 2025: 7 · 2024: 4 · 2023: 4
- FWCI
- 2.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Alzheimer s Disease (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Keywords
- donepezil, transdermal drug delivery
- MeSH terms
- Donepezil, Adolescent, Adult, Alzheimer Disease, Humans, Middle Aged, Cross-Over Studies, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.